Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/18/2018 06/19/2018 06/20/2018 06/21/2018 06/22/2018 Date
171.72(c) 173.05(c) 175.19(c) 172.49(c) 173.42(c) Last
1 577 453 2 034 259 2 744 292 1 248 173 1 931 345 Volume
-0.84% +0.77% +1.24% -1.54% +0.54% Change
More quotes
Financials (USD)
Sales 2018 15 289 M
EBIT 2018 7 368 M
Net income 2018 -1 127 M
Debt 2018 23 406 M
Yield 2018 1,58%
Sales 2019 15 621 M
EBIT 2019 7 517 M
Net income 2019 -156 M
Debt 2019 20 356 M
Yield 2019 1,60%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 5,38x
EV / Sales2019 5,07x
Capitalization 58 800 M
More Financials
Company
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International.The US Specialized Therapeutics segment includes sales and expenses relating to... 
Sector
Pharmaceuticals
Calendar
08/08Earnings Release
More about the company
Surperformance© ratings of Allergan plc
Trading Rating : Investor Rating :
More Ratings
Latest news on ALLERGAN PLC
06/21ALLERGAN : An Application for the Trademark "JUVEDERM VOLITE" Has Been Filed by ..
AQ
06/21ALLERGAN : Trademark Application for "LET ME BREAK IT DOWN FOR YOU" Filed
AQ
06/21ALLERGAN : Continues Active Board Refreshment Process
AQ
06/21ALLERGAN : Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR S..
AQ
06/18ALLERGAN : Continues Active Board Refreshment Process
AQ
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
06/15ALLERGAN : Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR I..
AQ
06/14ALLERGAN : Teams Up with a Host of Celebrities to Encourage Alzheimer's Patients..
AQ
06/14ABBOTT LABORATORIES : Allergan appoints former Abbott executive to its board
RE
06/14ALLERGAN : Continues Active Board Refreshment Process
PR
More news
Sector news : Pharmaceuticals - NEC
06/22Federal Judge Gives Lilly Win on Alimta Regimen Patent
DJ
06/22JOHNSON & JOHNSON : Remakes Top Leadership -- Update
DJ
06/22JOHNSON & JOHNSON : Worldwide Chairman Peterson to Retire
DJ
06/22SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/22Roche to Appoint James Sabry as Head of Partnering
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
06/22Up and Down the Ladder: Job Changes.. the latest comings and goings.. recogni.. 
06/22$AGN $APTX  
06/22Establishment Labs files for initial public offering  
06/21$WPI ALERT: New Allergan plc SEC Filing From our Stock News Alerts App 
06/21Pharmalot.. Pharmalittle.. Good Morning.. a rash of shortages for a new shing.. 
More tweets
Qtime:199
News from SeekingAlpha
06/22APTINYX : This Recent IPO Should Be On Your Radar 
06/21Establishment Labs files for initial public offering 
06/20EVOLUS : Botox Competitor Poised For Massive Growth 
06/18SYNERGY PHARMACEUTICALS : At Last A Glimmer Of Hope? 
06/15YOUR DAILY PHARMA SCOOP : Wright Receives PMA, Allergan And Corbus Report Positi.. 
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 206 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC5.45%58 800
JOHNSON & JOHNSON-12.27%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-12.58%191 785
MERCK AND COMPANY8.90%165 373